AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
February 16, 2017
-
February 02, 2017- If approved, G/P will provide an eight week, once-daily, ribavirin-free cure* for HCV patients without cirrhosis across all major genotypes
-
January 27, 2017- Reports Full-Year Diluted EPS of $3.63 on a GAAP Basis; Adjusted Diluted EPS of $4.82, Reflecting Growth of 12.4 Percent
-
January 25, 2017- Initiation of Phase 2 clinical trial programs in early Alzheimer's disease and progressive supranuclear palsy (PSP) is part of ongoing commitment to investigate ABBV-8E12 and tau-focused approaches to delay disease progression
-
January 24, 2017- If approved, G/P may provide a shorter, eight week, once-daily, ribavirin-free treatment option for the majority of HCV patients without cirrhosis
-
January 19, 2017- This marks the seventh FDA approval and fifth disease indication for IMBRUVICA since the medication's initial approval in 2013
-
January 10, 2017
-
January 09, 2017- Collaborations will focus on key therapeutic areas, including oncology and immunology
-
January 09, 2017- 99 percent (n=105/106) of genotype 1 (GT1) chronic HCV-infected Japanese patients without cirrhosis achieved SVR[12] with 8 weeks of G/P
-
December 22, 2016
-
December 19, 2016- If approved, G/P will provide an eight week once-daily, ribavirin-free treatment option for HCV patients without cirrhosis across all major genotypes
-
December 06, 2016- New Phase 2 data presented at the American Society of Hematology Annual Meeting highlight potential role of ibrutinib therapy beyond hematologic cancers
-
December 05, 2016- Data presented at the American Society of Hematology Annual Meeting show 48% overall response rate
-
December 05, 2016
-
December 04, 2016- New data available for ibrutinib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and in first-line follicular lymphoma (FL)
-
December 03, 2016- Nearly nine out of 10 patients (89%) with CLL/SLL achieve complete or partial response at five-year analysis
-
November 15, 2016- 98 percent of patients across all major HCV genotypes (GT1-6) with severe chronic kidney disease (CKD), including patients on dialysis, achieved SVR12 with 12 weeks of G/P in the primary intent-to-treat analysis, regardless of previous treatment status or presence of compensated cirrhosis
-
November 14, 2016- If approved by the European Commission, HUMIRA will be the first and only treatment option for patients aged 12 and older with hidradenitis suppurativa (HS), a painful, chronic inflammatory skin disease.
-
November 11, 2016- 97.5 percent of chronic HCV infected patients without cirrhosis and new to treatment across all major genotypes (GT1-6) achieved SVR12 with 8 weeks of G/P
-
November 04, 2016- Veliparib in combination with chemotherapy or radiation is being investigated in ongoing studies for advanced squamous non-small cell lung cancer (NSCLC)[1]
-
November 03, 2016- Results to be presented from ibrutinib clinical studies across multiple blood cancers
-
November 02, 2016
-
November 01, 2016
-
October 28, 2016
-
October 28, 2016- Reports Third-Quarter Diluted EPS of $0.97 on a GAAP Basis; Adjusted Diluted EPS of $1.21, Reflecting Growth of 7.1 Percent Over Third-Quarter 2015
-
October 19, 2016- Elagolix shows superiority compared to placebo in reducing daily menstrual and non-menstrual pelvic pain associated with endometriosis
-
October 10, 2016
-
October 06, 2016- New detailed results to be presented on primary and secondary efficacy and safety from two pivotal Phase 3 studies evaluating the use of Elagolix in endometriosis-associated pain
-
September 30, 2016- Breakthrough Therapy Designation granted based on Phase 2 clinical data for genotype 1 (GT1) patients who failed previous therapy with direct-acting antivirals (DAAs)
-
September 28, 2016- New site to expand the company's global operations for small molecule and biologics manufacturing
-
September 26, 2016- New Phase 2 open-label extension data to be presented on investigational biologic compound risankizumab, an anti-IL-23 monoclonal antibody, currently under investigation for moderate to severe chronic plaque psoriasis
-
September 26, 2016- If approved by the U.S. FDA, ibrutinib will be the first therapy specifically approved for patients with marginal zone lymphoma (MZL), a slow-growing form of non-Hodgkin's lymphoma, and the fifth new treatment indication for the medication
-
September 23, 2016- 98 percent of previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected patients without cirrhosis achieved SVR12 in Phase 3b GARNET study1
-
September 09, 2016
-
July 29, 2016- Reports Second-Quarter Diluted EPS of $0.98 on GAAP Basis; Adjusted Diluted EPS of $1.26, Reflecting Growth of 16.7 Percent Over Second-Quarter 2015
-
July 28, 2016- Trial will study efficacy and safety of venetoclax in combination with bortezomib and dexamethasone in patients who are considered sensitive or naïve to proteasome inhibitors who have received 1 to 3 prior lines of therapy for multiple myeloma(1)
-
July 25, 2016- New extended-release formulation is the first all-oral, co-formulated treatment containing the three direct-acting antiviral components of VIEKIRA PAK® for adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection
-
July 25, 2016- Collaboration will explore the safety and potential enhanced efficacy of combining checkpoint inhibitors with a cancer stem cell-targeting antibody drug conjugate in SCLC
-
July 25, 2016- The CHMP opinion represents a positive advance toward approval of the 12-week regimen of VIEKIRAX with ribavirin for genotype 4 (GT4) chronic hepatitis C virus (HCV) infected adult patients with or without compensated cirrhosis
-
July 11, 2016- DIPG are highly aggressive and difficult to treat brain tumors found at the base of the brain
-
July 07, 2016- Data from Phase 3 randomized, placebo controlled trial demonstrates that 46.6 percent of adult patients with moderate to severe psoriasis treated with HUMIRA® achieved at least a 75 percent improvement in their moderate to severe fingernail psoriasis
-
July 01, 2016
-
June 30, 2016- Non-infectious uveitis is an immune-mediated disease that can flare and impair vision
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
